

Antibody-Drug Conjugates (ADCs) Report

released by MabDesign
on January 11, 2017

MabDesign
321, Avenue Jean Jaurès
69007 Lyon – FRANCE
contact@mabdesign.fr

2016



Bâtiment Domilyon | 321 avenue Jean Jaurès 69007 Lyon
contact@mabdesign.fr | + 33 (0)4 78 02 39 88 | RCS 808 389 381




Table of Contents

INTRODUCTION	3
0. Abbreviations	4
1. What is an ADC ?	5
2. Advantages of ADCs and how they work	5
3. Key considerations when developing an ADC	6
3.1 Selecting the mAb	6
3.2 Selecting the cytotoxic payload	7
3.3 Selecting the linker	8
3.4 Attachment site	10
4. ADCs in clinical development	12
5. Bioanalysis of ADC and ADME characterization	22
6. Manufacturing Capabilities	25
7. Challenges in ADC development	26
7.1 Overcoming ADC therapy resistance	26
7.2 ADC toxicities	27
7.3 Challenges on ADCs effective tumor penetration	28
8. Future possibilities	29
8.1 Developing site-specific conjugation to improve the safety profiles	29
8.2 Discovery of new payloads	32
8.3 Combination therapy with immune checkpoints	32
8.4 Other possibilities	33
9. Conclusion	34
10. References	35

INTRODUCTION

MabDesign is a French non-profit membership organization in the immunotherapy field, operational since September 2015, already with more than 80 companies' members, including immunotherapy developers, service providers, training organizations and suppliers of state-of-the-art equipment.

MabDesign federates and supports the industrial sector through the creation of a national directory of stakeholders, by developing specialized training solutions, and setting up high-level scientific events both regional and international thus promoting networking and innovation.

Moreover, MabDesign has developed a set of services for companies in order to optimize their marketing positioning, increase their knowledge of their market, maximize the protection and valorization of their innovations (Business Intelligence & IP analysis) and finally conquer new markets internationally through support in business development, thus supporting their economic growth.

MabDesign is supported by a Scientific Advisory Board (*Comité d'orientation stratégique et scientifique de la filière* – COSSF) composed of 8 permanent experts, directed by its chairman, Alain Beck from Pierre-Fabre. The COSSF's mission is to contribute to the strategic scientific plans of action of MabDesign in the sector in order to foster innovation and economic development of companies as well as draft prospective reports on specific areas of the sector twice per year.

This document is a report on Antibody-Drug Conjugates drafted by the Scientific Advisory Board of MabDesign along with invited experts where you will be able to find a summary on the latest scientific progresses, clinical developments and stakeholders involved.

Scientific Advisory Board (COSSF)	Invited Experts	MabDesign
Alain Beck – Pierre Fabre	Anne Bousseau - GamamAbs	Nicolas Groux
Paul Baduel - Sanofi	Antoine Deslandes - Sanofi	Dominique Pons
Christophe de Romeuf - LFB	Sasha Koniev - Syndivia	Eva Cosson
Jean-Louis Pinquier - Medicien	Florence L'Hospice – Innate Pharma	Ana Antunes
Jean-François Prost - GamamAbs	Marie-Claude Viaud - McSAF	
Jérôme Tiollier – Innate Pharma		
Bernad Vanhove – OSE		
Immunotherapeutics		
Hervé Watier – Univ. Tours		


MabDesign accepts no liability for the accuracy or completeness of the information, advice or comment contained in this report nor any actions taken in reliance thereon. While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by MabDesign for its completeness or accuracy.

Table 0. Abbreviations used in this manuscript.

ABC	Adenosine triphosphate-binding cassette
Ab	Antibody
ADC	Antibody-drug conjugate
ADCC	Antibody-dependent cell-mediated cytotoxicity
ADME	Absorption, distribution, metabolism and excretion
ALCL	Anaplastic large-cell lymphoma
ALL	Acute lymphocytic leukemia
AML	Acute myeloid leukemia
CMO	Contract manufacturing organization
CRO	Contract research organization
CTLA-4	Cytotoxic T lymphocyte-associated protein-4
DAR	Drug to antibody ratio
DC	Dendritic cell
DLBCL	Diffuse large B-cell lymphoma
DM1	<i>N</i> (2')-deacetyl- <i>N</i> (2')-(3-mercapto-1-oxopropyl)-maytansine
DM4	<i>N</i> -methyl- <i>N</i> -(4-mercapto-4-methyl-1-oxopentyl)- <i>L</i> -alanine ester of maytansinol
EGFR	Epidermal growth factor receptor
EGFRvIII	Epidermal growth factor receptor mutant (exon deletion 2–7)
Fab	Fragment Antigen Binding
FDA	Food and Drug Administration
GPMB	Glycoprotein-NMB
HER2	Human epidermal growth factor receptor 2
HL	Hodgkin lymphoma
HPAPI	Highly potent active pharmaceutical ingredient
IC₅₀	Concentration needed to achieve 50% inhibition
mAb	Monoclonal antibody
MC	Maleimidocaproyl
MCC	Maleimidomethyl cyclohexane-1-carboxylate
MDR	Multidrug resistance
MMAE	Monomethyl auristatin E
MMAF	Monomethyl auristatin F
NHL	Non-Hodgkin lymphoma
NSCLC	Non-small cell lung cancer
P-gp	P-glycoprotein
PBD	Pyrrolobenzodiazepine
PEG	Polyethylene Glycol
PD	Pharmacodynamics
PD-1	Programmed cell death protein-1
PDX	Patient-derived xenograft
PK	Pharmacokinetic
PL	Phenylalanine-lysine dipeptide linker
RCC	Renal cell cancer
sALCL	Systemic anaplastic large-cell lymphoma
SCLC	Small cell lung cancer
scFv	Single-chain fragment variable
SPDB	<i>N</i> -succinimidyl-4-(2-pyridyldithio) butanoate
Sulfo-SPDB	<i>N</i> -succinimidyl-4-(2-pyridyldithio)-2-sulfo butanoate
VA	Valine-alanine dipeptide linker
VC	Valine-citrulline dipeptide linker

1. What is an ADC?

Antibody-drug conjugate (ADC) constitutes a novel class of highly potent biopharmaceutical drugs composed of an antibody (a whole monoclonal antibody-mAb, or an antibody fragment) conjugated to a cytotoxic drug through an appropriated linker (fig. 1). ADCs take advantage of the highly active cell-killing of cytotoxic molecules and their high binding specificity, while prolonging the half-life of cytotoxic molecules or decreasing their dose-limiting toxicity (Lu *et al.*, 2016).



<ul style="list-style-type: none"> - targets a well characterized and abundant tumor antigen associated with limited expression on healthy tissues - non-immunogenic - targets an antigen that is endocytosed after Ab binding - minimal non-specific binding - type of Ab format - FcγR-binding or not - FcRn binding affinity - Internalization & lysosomal trafficking 	<ul style="list-style-type: none"> - conjugation to lysines, hinge cysteines, engineered cysteines, non-natural amino acids... - variable drug-to-antibody ratio (DAR) 	<ul style="list-style-type: none"> - stable in systemic circulation - should efficiently release the cytotoxic drug inside the tumor cell - does not alter the Ab characteristics (PK) - selectively cleaved in or nearby the tumor cells - hydrazones, disulfides, peptides, non-cleavable 	<ul style="list-style-type: none"> - highly potent with IC₅₀ in subnanomolar range - non-toxic (dormant or inactive, prodrug) during systemic circulation - amenable to linker chemistry - define cell killing mechanism of action - tubulin inhibitors, DNA/RNA alkylators... - low off-target cytotoxicity - bystander effect - multidrug resistance escape - drug-drug interactions
---	--	--	--

Fig.1 – Key components of an ADC (adapted from Gébleux *et al.*, 2016).

2. Advantages of ADCs and how they work

The primary advantage of ADCs is that they can behave as prodrugs during systemic circulation and finally release the free drugs at the target tumor cells (fig. 2). Relying on highly targeted tumor antigen recognition and effective internalization, ADCs recognize and bind to specific tumor antigen on the cell surface, then the internalization is conducted through endocytosis. Once entering the tumor cells, ADCs are transferred to the endosome that fused to lysosome, allowing the digestion of the potential linkers or mAbs and actively release cytotoxic drugs (Lu *et al.*, 2016).

Pour obtenir ce rapport complet et profiter également d'autres avantages nous vous invitons à devenir membre de MabDesign.

Pour cela il vous suffit d'accéder à notre site web sur l'onglet Devenir Membre : <https://www.mabdesign.fr/devenir-membre/>

Pour en savoir plus sur les modalités d'adhésion vous pouvez nous contacter par email contact@mabdesign.fr ou nous joindre par téléphone au 04 78 02 39 88.

Bien cordialement,

L'équipe MabDesign

